A Phase I, 2-Panel, Open-Label Study in Healthy Subjects to Investigate the Pharmacokinetic Interaction Between TMC435 and the HMG-CoA Reductase Inhibitors Atorvastatin and Simvastatin

Trial Profile

A Phase I, 2-Panel, Open-Label Study in Healthy Subjects to Investigate the Pharmacokinetic Interaction Between TMC435 and the HMG-CoA Reductase Inhibitors Atorvastatin and Simvastatin

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Nov 2012

At a glance

  • Drugs Simeprevir (Primary) ; Atorvastatin; Simvastatin
  • Indications Cardiovascular disorders; Cystic fibrosis; Diabetic cardiomyopathy; Diabetic nephropathies; Heart failure; Hepatitis C; Hypercholesterolaemia; Hyperlipoproteinaemia type II; Hyperlipoproteinaemia type III; Hyperlipoproteinaemias; Hypertriglyceridaemia; Low HDL cholesterol
  • Focus Pharmacokinetics
  • Most Recent Events

    • 24 Sep 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top